OR WAIT null SECS
August 20, 2026
Video
Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.
August 09, 2026
Article
In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.
August 01, 2026
July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!
July 31, 2026
The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.
July 23, 2026
Ron Blankstein, MD, explains the value of PCD-CT and its consistency in both data collection and analysis of plaque with prior technology.
July 21, 2026
Ron Blankstein, MD, discusses a recent study confirming the replicability of CCTA results with AI-CPA in patients with coronary plaque at risk of cardiovascular disease.
According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.
July 20, 2026
Ron Blankstein, MD, discusses a secondary analysis of Heartflow’s DECIDE registry, indicating undetected cardiovascular risk in patients previously labeled safe.
July 17, 2026
Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.
July 13, 2026
Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.
